Summary of aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings on May 17, 2018

May 17, 2018 - By Nell Hawkins

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Total analysts of 3 have positions in aTyr Pharma (NASDAQ:LIFE) as follows: 0 rated it a “Buy”, 3 with “Sell” and 0 with “Hold”. The positive are 0. Since February 14, 2018 according to StockzIntelligence Inc aTyr Pharma has 3 analyst reports. On Wednesday, February 14 the stock has “Underweight” rating by JP Morgan. In Wednesday, February 14 report J.P. Morgan downgraded the stock to “Sell” rating. On Tuesday, May 15 the stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Sell” rating by Citigroup. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

Ticker’s shares touched $0.95 during the last trading session after 11.20% change.aTyr Pharma, Inc. is downtrending after having declined 19.01% since May 17, 2017. LIFE has 1.04 million volume or 681.58% up from normal. The stock underperformed the S&P 500 by 30.56%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The firm is valued at $28.17 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Last it reported negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

For more aTyr Pharma, Inc. (NASDAQ:LIFE) news brought out recently go to: Benzinga.com, Benzinga.com, Nasdaq.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” brought out on May 16, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” on May 17, 2018, “Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide” with a publish date: May 14, 2018, “Premarket analyst action – healthcare” and the last “aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 …” with publication date: May 17, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.